1. Ascherio A, Katan MB, Zock PL, et al. Trans fatty acids and coronary heart disease. N Engl J Med1999;340:1994–1998.
2. Lichtenstein AH. Trans fatty acids, plasma lipid levels, and risk of developing cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation1997;95:2588–2590.
3. Lopez-Garcia E, Schulze MB, Manson JE, et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr 2004;134:1806–1811.
4. Baer DJ, Judd JT, Clevidence BA, et al. Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. Am J Clin Nutr 2004;79:969–973.
5. Mozaffarian D, Pischon TT, Hankinson SE, et al. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr 2004;79:606–612.
6. Stender S, Dyerberg J. Influence of trans fatty acids on health. Ann Nutr Metab 2004;48:61–66.
7. Food and Drug Administration. Food Labeling: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims. Federal Register: 68 FR 41433 July 11, 2003.
8. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiography. Proc Natl Acad Sci 2002;99:15596–15601.
9. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos.Am J Clin Nutr 1975;28:958–966.
10. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in northwestern Greenland.Am J Clin Nutr 1980;33:2657–2661.
11. Jho DH, Cole SM, Lee EM, et al. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther 2004;3:98–111.
12. Simopoulos AP. Omega-3 fatty acids in inflammation and auto-immune disease. J Am Coll Nutr2002;21:495–505.
13. Babcock T, Helton WS, Espat NJ. Eicosapentaenoic acid (EPA): an anti-inflammatory omega-3 fat with potential clinical applications. Nutrition 2000;16:1116–1118.
14. Jho DH, Babcock TA, Helton WS, et al. Omega-3 fatty acids: implication for the treatment of tumor associated inflammation. Am Surg 2003;69:32–36.
15. Obata T, Nagakura T, Masaki T, et al. Eicosapentaenoic acid inhibits prostaglandin D2 generation by inhibiting cyclo-oxygenase-2 in cultured human mast cells. Clin Exp Allergy 1999;29:1129–1135.
16. RingbomT, Huss U, Stenholm A, et al. Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod 2001;64:745–749.
17. Babcock TA, Helton WS, Hong D, et al. Omega-3 fatty acid lipid emulsion reduces LPS-stimulated macrophage TNF-alpha production. Surg Infect (Larchmt) 2002;3:145–149.
18. Novak TE, Babcock TA, Jho DH, et al. NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol2003;284:L84–L89.
19. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002;56:365–379.
20. Johnson K. The glycemic index, in Rakel D (ed): Integrative Medicine. Philadelphia, WB Saunders, 2003, pp 661–666.
21. Foster-Powerll K, Holt SH, Barnd-Miller JC. International table of glycemic index and glycemic load values. Am J Clin Nutr 2002;76:55–56.
22. Wolever TM, David JA, Jenkins, et al. The glycemic index: methodology and clinical applications.Am J Clin Nutr 1991;54:846–854.
23. Wolever TM. The glycemic index: aspects of some vitamins, minerals, and enzymes in health and disease. World Rev Nutr Diet 1990;62:120–185.
24. Schulze MB, Liu S, Rimm EB, et al. Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle aged women. Am J Clin Nutr 2004;80:348–356.
25. Das UN. Is insulin an endogenous cardioprotector? Crit Care 2002;6:389–393.
26. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC): Potsdam Study. Diabetes 2003;52:812–817.
27. Liu S, Manson JE, Buring JE, et al. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002;75:492–498.
28. Liu S, Willett WC, Stampfer MJ, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 2000;71:1455–1461.
29. Augustin LS, Gallus S, Negri E, et al. Glycemic index, glycemic load, and risk of gastric cancer.Ann Oncol 2004;15:581–584.
30. Higginbotham S, Zhang ZF, Lee IM, et al. Dietary glycemic load and risk of colorectal cancer in the Women’s Health Study. J Natl Cancer Inst 2004;96:229–233.
31. Augustin LS, Gallus S, Franceschi S, et al. Glycemic index and load and risk of upper aero-digestive tract neoplasms. Cancer Causes Control 2003;14:657–662.
32. Folsom AR, Demissie Z, Harnack L. Glycemic index, glycemic load, and incidence of endometrial cancer: the Iowa Women’s Health Study. Nutr Cancer 2003;46:119–124.
33. Michaud DS, Liu S, Giovannucci E, et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002;94:1293–1300.
34. Holmes MD, Liu S, Hankinson SE, et al. Dietary carbohydrates, fiber, and breast cancer risk. Am J Epidemiol 2004;159:732–739.
35. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the ATTICA study. J Am Coll Cardiol2004;44:152–158.
36. Barzi F, Woodward M, Marfisi RM, et al. Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial. Eur J Clin Nutr 2003;57:604–611.
37. Marchioli R. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. Minerva Cardioangiol 2003;51:561–576.
38. Augustine MB. Integrative approach to nutrition, in Kligler B, Lee R (eds): Integrative Medicine: Principles for Practice. New York, McGraw Hill, 2004.
39. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade–eicosanoids, cyclooxygenases, and lipoxygenases–as an adjunct in cancer therapy. Integr Cancer Ther 2002;1:7–37.
40. Maes M, Christophe A, Bosmans E, et al. In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biol Psychiatry 2000;47:910–920.
41. Miller GE, Freedland KE, Carney RM, et al. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun 2003;17:276–285.
42. Danner M, Kasl SV, Abramson JL, et al. Association between depression and elevated C-reactive protein. Psychosom Med 2003;65:347–356.
43. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2004;164:1010–1014.
44. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people: the ATTICA study. Eur Heart J 2004;25:492–499.
45. Yirmiya R. Depression in medical illness: the role of the immune system. West J Med2000;173:333–336.
46. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology 2002;13:561–568.
47. Wearden AJ, Morriss RK, Mullis R, et al. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 1998;172:485–490.
48. Ferroni P, Basili S, Falco A, et al. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 2004;6:424–431.
49. Vazquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab 2004;90:316–322.
50. King DE, Mainous AG, Pearson WS. C-reactive protein, diabetes, and attendance at religious services. Diabetes Care 2002;25:1172–1176.
51. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458–462.
52. Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004;16:199–205.